Archives
-
Angiotensin 1/2 (2-7) Research Workflows
2026-09-16
Use Angiotensin 1/2 (2-7) as a defined peptide input for renin-angiotensin signaling pathway studies, vascular-response assays, and receptor-binding experiments. Its short sequence also provides a practical bridge to emerging work on angiotensin-modulated SARS-CoV-2 spike–receptor interactions.
-
Resazurin Cell Viability Assay Kit Workflow
2026-09-16
Build a sensitive, non-destructive cell viability assay around resazurin reduction, with practical guidance for screening, dose-response studies, and mechanistic oncology workflows. This article translates findings from parthenolide-treated lymphoid malignancy models into assay design, controls, troubleshooting, and orthogonal validation strategies.
-
Angiotensin I Workflows for RAS Research
2026-09-15
Turn Angiotensin I into a controlled substrate for ACE activity studies, antihypertensive drug screening, and cardiovascular mechanism experiments. This practical guide combines peptide handling, assay controls, neuroendocrine study design, and a data-quality lesson from fluorescence spectroscopy research.
-
Angiotensin I (Human, Mouse, Rat): Research Guide
2026-09-15
Angiotensin I is a decapeptide precursor that connects renin activity to angiotensin II generation in renin-angiotensin system research. The A1006 product supports cardiovascular, neuroendocrine, and antihypertensive drug screening workflows when investigators distinguish the precursor from the active Ang II product.
-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-09-14
The referenced preprint shows that selected kinase inhibitors can do more than block p38α MAP kinase catalysis: they can also accelerate WIP1-mediated dephosphorylation by reshaping the kinase activation loop. This structural mechanism provides a framework for designing experiments that distinguish direct active-site inhibition from phosphatase-assisted signal termination.
-
Toremifene Citrate: Practical ER Workflows
2026-09-14
Translate estrogen receptor pharmacology into reproducible cell-based, binding, and translational workflows with Toremifene Citrate. The guide emphasizes concentration design, matched tamoxifen comparisons, assay controls, and troubleshooting for breast cancer research.
-
GRE Combination Inhibits Melanogenesis: Study Analysis
2026-09-13
This study evaluates a composition of glabridin, resveratrol, and ellagic acid (GRE) across melanogenesis, oxidative-stress, and inflammation-related assays. Its main contribution is a multi-readout comparison linking reduced melanin and tyrosinase activity with suppression of CREB phosphorylation and MITF-associated signaling, while also identifying antioxidant and nitric oxide-lowering activity in vitro.
-
Bestatin Hydrochloride: A Conversion-Aware Assay Guide
2026-09-12
Bestatin hydrochloride, also known as Ubenimex, is a powerful probe for connecting aminopeptidase activity with neuronal signaling, angiogenesis inhibition, and tumor biology. This guide focuses on conversion-aware assay design, controls, and interpretation rather than repeating a conventional product summary.
-
Safe DNA Gel Stain for RNAi Gel Workflows
2026-09-11
Safe DNA Gel Stain supports safer DNA and RNA gel stain workflows for RNAi and developmental biology. This guide connects blue-light nucleic acid visualization with assay decisions inspired by MroGCL research in giant prawn spermatogenesis.
-
a-MSH, amide: A Causal Lens on Melanogenesis
2026-09-11
a-MSH, amide is an alpha-melanocyte-stimulating hormone amide for controlled melanogenesis studies. This article explains how to use it as a causal perturbation, interpret CREB/MITF evidence, and separate pigmentation from inflammatory readouts.
-
FAISL, Calpain 2, and FAK Stability in TNBC
2026-09-10
A 2024 Advanced Science study identifies FAISL as a long non-coding RNA that stabilizes focal adhesion kinase by blocking calpain 2-mediated proteolysis. By combining TCGA analysis, RNA immunoprecipitation sequencing, mechanistic cell studies, and nanoparticle-delivered siRNA, the work connects RNA-dependent protein stability with triple-negative breast cancer progression and metastasis.
-
Sulfo-NHS-LC-Biotin: Practical Labeling Guide
2026-09-10
Sulfo-NHS-LC-Biotin is a water-soluble, membrane-impermeable reagent for covalent biotinylation of accessible primary amines on proteins, peptides, and cell-surface proteins. This guide covers aqueous labeling, cleanup, and streptavidin capture while defining why the reagent is unsuitable for reversible or intracellular labeling.
-
BFH772 (VEGFR2 inhibitor): Workflow Guide
2026-09-09
BFH772 is a selective small-molecule VEGFR2 inhibitor for target-focused kinase, cellular, and angiogenesis research where organic-solvent stocks are acceptable. Its water insolubility, storage requirements, and lack of directly matched paper evidence make solvent control, fresh working solutions, and independent assay validation essential.
-
Bestatin, Amastatin, and Brain Angiotensin Signaling
2026-09-09
Harding and Felix used local aminopeptidase inhibition and microiontophoretic recording to test whether angiotensin II requires conversion to angiotensin III for neuronal activation. Their results support a sequential processing model in which aminopeptidase A participates in angiotensin II conversion, while bestatin-sensitive peptidase activity helps regulate the resulting signal.
-
Drug Response Metrics in Cancer Research
2026-09-08
Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a more discriminating in vitro framework that separates growth inhibition from cell killing and emphasizes their distinct proportions and timing.